Cargando…

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

OBJECTIVE: In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control in type 2 diabetes uncontrolled with GLP-1 RAs over 26 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blonde, Lawrence, Rosenstock, Julio, Frias, Juan, Birkenfeld, Andreas L., Niemoeller, Elisabeth, Souhami, Elisabeth, Ji, Chen, Del Prato, Stefano, Aroda, Vanita R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	Emerging Therapies: Drugs and Regimens
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896258/ https://www.ncbi.nlm.nih.gov/pubmed/33468520 http://dx.doi.org/10.2337/dc20-2023

Ejemplares similares

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial
por: Del Prato, Stefano, et al.
Publicado: (2020)

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening
por: Rosenstock, Julio, et al.
Publicado: (2021)

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L
por: Zisman, Ariel, et al.
Publicado: (2018)

iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L
por: Niemoeller, Elisabeth, et al.
Publicado: (2017)

Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results
por: Guja, Cristian, et al.
Publicado: (2021)

More patients reach glycaemic control with a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time‐to‐control analysis of LixiLan‐O and LixiLan‐L
por: Frias, Juan, et al.
Publicado: (2018)

Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan‐O randomized trial
por: Davies, Melanie J., et al.
Publicado: (2021)

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study
por: Morea, Nicola, et al.
Publicado: (2020)

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan‐L trial
por: Wysham, Carol, et al.
Publicado: (2017)

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial
por: Giorgino, Francesco, et al.
Publicado: (2019)

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980
por: Aroda, Vanita R., et al.
Publicado: (2017)

Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
por: Rosenstock, Julio, et al.
Publicado: (2021)

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
por: Davies, Melanie J., et al.
Publicado: (2017)

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
por: Skolnik, Neil, et al.
Publicado: (2021)

iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
por: Yabe, Daisuke, et al.
Publicado: (2021)

Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial
por: Hramiak, Irene, et al.
Publicado: (2022)

Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial
por: Yuan, Xiaoyong, et al.
Publicado: (2022)

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035
por: Rosenstock, Julio, et al.
Publicado: (2017)

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
por: Blonde, Lawrence, et al.
Publicado: (2020)

Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers
por: Yale, Jean-François, et al.
Publicado: (2022)

Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial
por: Davies, Melanie J., et al.
Publicado: (2019)

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials
por: Davidson, J. A., et al.
Publicado: (2019)

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
por: Home, Philip D., et al.
Publicado: (2022)

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial
por: Frias, Juan Pablo, et al.
Publicado: (2022)

Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study
por: Xie, Panpan, et al.
Publicado: (2023)

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
por: McCrimmon, Rory J., et al.
Publicado: (2021)

Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
por: Polonsky, William H., et al.
Publicado: (2022)

Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison
por: Home, Philip D., et al.
Publicado: (2021)

Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study
por: Chauhan, Ankita, et al.
Publicado: (2023)

Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
por: McCrimmon, Rory J., et al.
Publicado: (2021)

Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study
por: Matsuhisa, Munehide, et al.
Publicado: (2022)

Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus
por: Ken-Opurum, Jennifer, et al.
Publicado: (2023)

Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial
por: Iizuka, Katsumi, et al.
Publicado: (2021)

iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
por: Hinnen, Debbie, et al.
Publicado: (2018)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
por: Shao, Hui, et al.
Publicado: (2022)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9l5qf8ufj5apdu8dt6vqbi0icv